Increasing membrane polyunsaturated fatty acids sensitizes non-small cell lung cancer to anti-PD-1/PD-L1 immunotherapy
Cancer Letters · 2024-11 · 604 · 217221
DOI: 10.1016/j.canlet.2024.217221 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024-11. Verfasst von Sofia La Vecchia und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology University of Torino, Italy. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, B7-H1 Antigen, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dell’Istruzione, dell’Università e della Ricerca, Fondazione Guido Berlucchi, Governo Italiano Ministero dell'Istruzione dell'Universita e della Ricerca.
Abstract (Originalsprache)
Immune checkpoints inhibitors (ICIs) as anti-PD-1/anti-PD-L1 have been approved as first-line treatment in patients with non-small cell lung cancer (NSCLC), but only 25 % of patients achieve durable response. We previously unveiled that estrogen receptor α transcriptionally up-regulates PD-L1 and aromatase inhibitors such as letrozole increase the efficacy of pembrolizumab. Here we investigated if letrozole may have additional immune-sensitizing mechanisms. We found that higher the level of PD-L1 in NSCLC, higher the activation of SREBP1c that transcriptionally increases fatty acid synthase and stearoyl-CoA desaturase enzymes, increasing the amount of polyunsaturated fatty acids (PUFAs). Letrozole further up-regulated SREBP1c-mediated transcription of lipogenic genes, and increased the amount of PUFAs, thereby leading to greater membrane fluidity and reduced binding between PD-L1 and PD-1. The same effects were observed upon supplementation with ω3-PUFA docosahexaenoic acid (DHA) that enhanced the efficacy of pembrolizumab in humanized NSCLC immune-xenografts. We suggest that PUFA enrichment in membrane phospholipids improves the efficacy of ICIs. We propose to repurpose letrozole or DHA as new immune-sensitizing agents in NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology University of Torino, Italy.
- Department of Oncology University of Torino, Italy; Molecular Biotechnology Center "Guido Tarone", University of Torino, Italy.
- Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), UCLouvain, Brussels, Belgium.
- Department of Oncology University of Torino, Italy; Molecular Biotechnology Center "Guido Tarone", University of Torino, Italy. Electronic address: chiara.riganti@unito.it.
Förderung
- Ministero dell’Istruzione, dell’Università e della Ricerca
- Fondazione Guido Berlucchi
- Governo Italiano Ministero dell'Istruzione dell'Universita e della Ricerca
- Associazione Italiana per la Ricerca sul Cancro
Zitieren
APA
La Vecchia, S., Fontana, S., Salaroglio, I. C., Anobile, D. P., Digiovanni, S., Akman, M., Jafari, N., Godel, M., Costamagna, C., Corbet, C., Kopecka, J., & Riganti, C. (2024). Increasing membrane polyunsaturated fatty acids sensitizes non-small cell lung cancer to anti-PD-1/PD-L1 immunotherapy. Cancer Letters, 604, 217221. https://doi.org/10.1016/j.canlet.2024.217221
Vancouver
La Vecchia S, Fontana S, Salaroglio IC, Anobile DP, Digiovanni S, Akman M, et al. Increasing membrane polyunsaturated fatty acids sensitizes non-small cell lung cancer to anti-PD-1/PD-L1 immunotherapy. Cancer Letters. 2024;604:217221. doi:10.1016/j.canlet.2024.217221
BibTeX
@article{LaVecchia2024,
author = {La Vecchia, Sofia and Fontana, Simona and Salaroglio, Iris Chiara and Anobile, Dario Pasquale and Digiovanni, Sabrina and Akman, Muhlis and Jafari, Niloufar and Godel, Martina and Costamagna, Costanzo and Corbet, Cyril and Kopecka, Joanna and Riganti, Chiara},
title = {Increasing membrane polyunsaturated fatty acids sensitizes non-small cell lung cancer to anti-PD-1/PD-L1 immunotherapy},
journal = {Cancer Letters},
year = {2024},
volume = {604},
pages = {217221},
doi = {10.1016/j.canlet.2024.217221}
}
EUVIMED